# NeuroKaire

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurokaire

- Industry: Biotechnology
- Headquarters: Tel Aviv, Israel
- Website: www.neurokaire.com
- Total disclosed funding: $10M
- Latest round: Series A (Sep 30, 2021)
- Investors on record: 4

## About

Based in Israel, NeuroKaire develops innovative precision medicine solutions for central nervous system diseases, transforming psychiatric and neurological care through advanced AI-enabled technologies.NeuroKaire, founded in 2017 in Tel Aviv, Israel, specializes in precision medicine focused on CNS diseases. The company has engaged in 3 total deals, with its most recent funding round occurring on December 17, 2024. The company raised USD 10.000 mn led by GreyBird Ventures, with participation from JumpSpeed Ventures and Meron Capital. Talia Solal is the current CEO, while Daphna Laifenfeld serves as the founder.NeuroKaire specializes in precision medicine for central nervous system (CNS) diseases, leveraging Nobel-Prize winning technology to develop innovative solutions. The company's core offerings include advanced, AI-enabled tests and services that utilize patient-derived induced pluripotent stem cells (iPSCs) to create neurons for personalized treatment strategies. This process begins with a simple blood sample collection, which is converted into neuronal subtypes reflective of the patient's unique neurobiology. NeuroKaire’s technology integrates multi-modal data to provide actionable insights into drug efficacy and individual patient responses, primarily serving clinicians, researchers, and biopharmaceutical developers across global markets, including North America, Europe, and parts of Asia.NeuroKaire's revenue model is based on providing specialized tests and services to healthcare providers and biopharma companies. The company fosters partnerships that advance treatment optimization and drug development through direct engagements with healthcare institutions and pharmaceutical developers. Revenue is generated from service agreements, which may involve fees for the use of proprietary technology and data analysis services, along with potential subscription models for ongoing access to its comprehensive biobank and data repository. Its flagship offerings related to individual patient neuron analysis and drug responsiveness scoring are critical for clinicians tailoring treatment plans based on unique patient profiles.In December 2024, NeuroKaire raised USD 10.000 mn in venture funding to scale operations and expand its team. The company plans to deepen research and development and grow its network of pharmaceutical partnerships to advance precision medicine in mental health. Specific upcoming products are designed to enhance treatment strategies, while the funding will support expansion into new markets, particularly targeting regions in Europe and Asia by the end of 2025.

## Funding rounds

- Series A, Sep 30, 2021, $10M — JumpSpeed Ventures, GreyBird Ventures, Meron Capital, Sapir Venture Partners

## Investors

- JumpSpeed Ventures (https://capitalatlas.ai/funds/jumpspeed-ventures) — Series A
- GreyBird Ventures (https://capitalatlas.ai/funds/greybird-ventures) — Series A
- Meron Capital (https://capitalatlas.ai/funds/meron-capital) — Series A
- Sapir Venture Partners (https://capitalatlas.ai/funds/sapir-venture-partners) — Series A